Pfizer launches next-gen vaccine for pneumococcal disease
Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive pr...
The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement.
It enables timely and proactive protection for all adults, including those living with chronic conditions, it added.
PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said.
"We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.